Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fate TherapeuticsFATE +0.78%33 Days Sales Outstanding is 30.83 as of Jun. 2026, which is 55% below its 10-year median of 67.94. GuruFocus rates FATE with a GF Score™ of 33/100 and a GF Value™ of $0.78 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 835 Biotechnology companies, Fate Therapeutics ranks better than 65.63% on this metric.
Fate Therapeutics (NAS:FATE) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Fate Therapeutics Days Sales Outstanding Related Terms
Fate Therapeutics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Fate Therapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FATE vs IMRX, NWBO, FHTX: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Fate Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fate Therapeutics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Fate Therapeutics's Days Sales Outstanding falls into.
Fate Therapeutics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fate Therapeutics (FATE) has a Days Sales Outstanding of 30.83 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Fate Therapeutics and its competitors. This is 55% below median its historical median of 67.94. Over the past decade, Fate Therapeutics' Days Sales Outstanding has ranged from 17.09 to 122.33. According to the industry distribution chart, Fate Therapeutics ranks #287 out of 835 companies in the Biotechnology industry, placing it in the top 34.4%.
Is Fate Therapeutics' Days Sales Outstanding too high?
Fate Therapeutics' current Days Sales Outstanding of 30.83 is 55% below median its 10-year median of 67.94. Over the past 10 years, this metric has ranged from a low of 17.09 to a high of 122.33. The Biotechnology industry median Days Sales Outstanding is 68.94. Fate Therapeutics' value of 30.83 is 55.3% below this industry median. Based on the distribution chart, Fate Therapeutics ranks #287 out of 835 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fate Therapeutics has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fate Therapeutics' Days Sales Outstanding compare to IMRX and NWBO?
According to the Biotechnology industry distribution chart, Fate Therapeutics ranks #287 out of 835 companies for Days Sales Outstanding. This puts Fate Therapeutics in the upper half of its industry. The industry median Days Sales Outstanding is 68.94. Fate Therapeutics' value of 30.83 is 55.3% below this benchmark. Historically, Fate Therapeutics' own Days Sales Outstanding has ranged from 17.09 to 122.33 over the past decade. While the company's 10-year median is 67.94 vs. the industry median of 68.94, Fate Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fate Therapeutics's current Days Sales Outstanding of 30.83 is 55.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Fate Therapeutics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fate Therapeutics's current Days Sales Outstanding is 30.83, which is 55% below median its own 10-year median of 67.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fate Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Fate Therapeutics (FATE) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.78, compared to a current price of $2.57 — trading 229.5% above its estimated fair value. The current Days Sales Outstanding is 30.83, which is 55% below median its 10-year median of 67.94 and 55.3% below the Biotechnology industry median of 68.94. Fate Therapeutics' overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Fate Therapeutics (FATE), the current Days Sales Outstanding is 30.83 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fate Therapeutics (FATE) Overvalued in 2026?
Based on GuruFocus' analysis, Fate Therapeutics stock appears to be overvalued.
The current stock price of $2.57 is trading 229.5% above its estimated GF Value™ of $0.78.
GuruFocus considers Fate Therapeutics to be Significantly Overvalued.
Key valuation signals for FATE:
Days Sales Outstanding: 30.83 (55% below median its 10-year median of 67.94)
GF Value™: $0.78 vs. price of $2.57 (229.5% above fair value)
Industry Position: 55.3% below the Biotechnology median (#287 of 835)
No single metric tells the full story. See the FATE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
33GF Score
Get the complete analysis for FATE
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FATE has been successfully added to your 
